Publication | Closed Access

MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma

Neuro-oncologySurvival BenefitTumoral PathologyGliomaMedicineMgmt Promoter HypermethylationPathologyHigh-grade GliomasRecurrent Anaplastic AstrocytomaCancer TreatmentOncologyCell BiologyTumor Biology